UK Markets open in 3 hrs 20 mins

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.93+0.17 (+2.95%)
At close: 04:00PM EDT
5.93 0.00 (0.00%)
After hours: 05:00PM EDT

Erasca, Inc.

10835 Road to the Cure
Suite 140
San Diego, CA 92121
United States
858 465 6511

Full-time employees123

Key executives

NameTitlePayExercisedYear born
Dr. Jonathan E. Lim M.D.Co-Founder, Chairman & CEO480kN/A1972
Dr. David M. Chacko M.D.Chief Financial Officer455.3kN/A1984
Dr. Michael D. Varney Ph.D.Chairman of R&D, Scientific Advisory Board member and Director26.3kN/A1958
Dr. Nik Chetwyn Ph.D.Sr. VP of OperationsN/AN/AN/A
Mr. Ebun S. Garner J.D., Esq.Gen. Counsel & Corp. Sec.N/AN/A1972
Dr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerN/AN/AN/A
Dr. Wei Lin M.D.Chief Medical OfficerN/AN/A1970
Mr. Brian L. Baker CPA, M.S., MS, CPASr. VP of Fin.N/AN/A1967
Ms. Chandra D. LovejoySr. VP of Regulatory AffairsN/AN/A1971
Dr. Robert Shoemaker Ph.D.Sr. VP of ResearchN/AN/A1981
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Corporate governance

Erasca, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.